Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.060
-0.170 (-4.02%)
At close: Nov 13, 2025, 4:00 PM EST
4.020
-0.040 (-0.98%)
After-hours: Nov 13, 2025, 7:56 PM EST
Altimmune Employees
Altimmune had 59 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
59
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$339
Profits / Employee
-$1,422,288
Market Cap
423.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | 43 | 18 | 72.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALT News
- 2 days ago - Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 6 days ago - Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 7 days ago - Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Altimmune Announces Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 8 days ago - Altimmune to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder - GlobeNewsWire
- 14 days ago - Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - GlobeNewsWire
- 24 days ago - Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025 - GlobeNewsWire